What is the current Price Target for the Homology Medicines, Inc. stock?

The average Homology Medicines, Inc. target price is $8.16. This is 253.25% higher than the current stock price. The highest price target is 809.09%, the lowest is 74.89%. 6 Analysts have issued a price target Homology Medicines, Inc. 2026 .

How high will the Homology Medicines, Inc. stock rise?

No reliable answer can be given as to how high the Homology Medicines, Inc. stock will rise. The performance of stocks, including the Homology Medicines, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Homology Medicines, Inc. stock today?

The performance of Homology Medicines, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Homology Medicines, Inc. stock fall?

The decline in Homology Medicines, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Homology Medicines, Inc. Forecast, price target & analysts

$2.31

1.28% yesterday

Nasdaq, Jul 24, 10:05 pm CET

ISIN

US4380831077

Symbol

QTTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Homology Medicines, Inc. Target price 2025 - Analyst rating & recommendation

Homology Medicines, Inc. Classifications & Recommendation:

Buy

60%

Hold

40%

Homology Medicines, Inc. Price Target

Target Price	$8.16
Price	$2.31
Potential	253.25% register free of charge
Number of Estimates	6

	6 Analysts have issued a price target Homology Medicines, Inc. 2026 . The average Homology Medicines, Inc. target price is $8.16. This is 253.25% register free of charge higher than the current stock price. The highest price target is $21.00 809.09% register free of charge , the lowest is $4.04 74.89% register free of charge .
	A rating was issued by 10 analysts: 6 Analysts recommend Homology Medicines, Inc. to buy, 4 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Homology Medicines, Inc. stock has an average upside potential 2026 of 253.25% register free of charge . Most analysts recommend the Homology Medicines, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-5.15	-4.38
	85.37%	14.95%
P/E		negative

6 Analysts have issued a Homology Medicines, Inc. forecast for earnings per share. The average Homology Medicines, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-5.15	85.37%
2025	$-4.38 14.95% Unlock
2026	$-4.52 3.20% Unlock
2027	$-6.60 46.02% Unlock

Current	-0.46	91.48%
2025	-0.53 13.25% Unlock
2026	-0.52 1.89% Unlock
2027	-0.35 32.69% Unlock

Homology Medicines, Inc....

Current Homology Medicines, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Wells Fargo	Locked ➜ Locked	Locked	Mar 12 2025
BMO Capital	Locked ➜ Locked	Locked	Feb 11 2025
Piper Sandler	Locked ➜ Locked	Locked	Feb 11 2025
BMO Capital	Locked ➜ Locked	Locked	Dec 12 2024
Guggenheim	Locked ➜ Locked	Locked	Dec 12 2024
Leerink Partners	Locked ➜ Locked	Locked	Dec 11 2024
Oppenheimer	Locked ➜ Locked	Locked	Dec 11 2024

Analyst Rating	Date
Locked Wells Fargo: Locked ➜ Locked	Mar 12 2025
Locked BMO Capital: Locked ➜ Locked	Feb 11 2025
Locked Piper Sandler: Locked ➜ Locked	Feb 11 2025
Locked BMO Capital: Locked ➜ Locked	Dec 12 2024
Locked Guggenheim: Locked ➜ Locked	Dec 12 2024
Locked Leerink Partners: Locked ➜ Locked	Dec 11 2024
Locked Oppenheimer: Locked ➜ Locked	Dec 11 2024

Discover more stocks with a high price target

Alibaba Group Holding Ltd 23.74%

BioNTech SE - ADR 22.41%

Deutsche Telekom 21.05%

Infineon 20.35%

MongoDB 19.28%

Tencent Holdings Ltd. 17.02%

Rheinmetall 16.00%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now